Prostaglandin analogs for preventing the progression of diabetic nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040170

Enrollment

Unknown

Registered

2020-11-23

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy

Interventions

Experimental group:Combination of Prostaglandin E1 and Prostaglandin I2 analogue

Control group:Routine treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old when recruiting participants; 2. Patients with type 1 or type 2 diabetes; 3. Patients with clinically diagnosed or biopsy-proven DN; 4. Diabetic complications with or without multiple organs; 5. The estimated survival time more than half a year; 6. Agreement to participant in this trial with informed consent signed.

Exclusion criteria

Exclusion criteria: 1. Patients with clinically suspected or biopsy-conformed non-diabetic kidney disease; 2. Bleeding tendency or being taking anticoagulants or antiplatelet drugs; 3. Allergic tendency or known allergy to drug ingredient; 4. Pregnancy or lactation; 5. Participation in another trial at the same period.

Design outcomes

Primary

Measure	Time frame
a composite of ESRD, doubling of SCr or 50% reduction in GFR;	—

Countries

China

Contacts

Public ContactWenge Li

China-Japan Friendship Hospital

wenge_lee2002@126.com+86 010-84205346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026